Amarin has been an exciting stock to follow since the company gained approval from the Food and Drug Administration for its triglyceride-lowering drug Vascepa this summer. The FDA's delay in deciding whether Vascepa qualifies for NCE status has weighed heavily on the stock, but buyout speculation has buoyed Amarin's share price lately.
Recently, British newspaper The Daily Mail suggested that pharma giant AstraZeneca (NYSE:AZN) might be interested in adding Vascepa to its product portfolio. While an Amarin buyout could just be speculation -- and neither company has publicly initiated negotiations -- could this deal hypothetically make sense? Would this be the right acquisition for AstraZeneca? Given that Vascepa's NCE status is still not final, would the timing be right?
In the following video, health care analysts Max Macaluso and Brenton Flynn take an in-depth look at these issues.
The biotech space can make or break investors over-night, and, while Amarin's future is still unclear, the company could have huge potential. If you're an investor looking for more insight on Amarin, don't invest a dollar before reading everything you need to know about Amarin. This new premium research report can help you weigh the opportunities and risks associated with this stock. Click here now to keep reading.
Max Macaluso, Ph.D. and Brenton Flynn have no positions in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.